News Focus
News Focus
icon url

MayoMobile

11/24/25 10:02 AM

#509594 RE: AlchemicalVoyager13 #509586

My projections were based on ABCLEAR1 as the primary target population. It seems likely Anavex will be approved at re-eval with a narrower indication (ABCLEAR1). GLP-1 failure assists these market penetration forecasts.

For now, nothing has changed.

Curious what Missling will say tomorrow.